GLP-1 Medications and Stomach-Emptying Tests: Preparing for a Motility Study

A GLP-1 slows gastric emptying by design, so it can skew a motility test; here is how to coordinate any hold with the clinician who ordered it.

You told your doctor about the nausea, the early fullness, the feeling that food just sits there. So they ordered a gastric emptying study, sometimes called scintigraphy, to measure how fast your stomach actually clears a meal. Then someone at the imaging center asks whether you are on a GLP-1 medication like semaglutide or tirzepatide, and now you have questions. Do you hold it? For how long? Who decides? This is a coordination question, not a treatment change you make on your own, and the honest answer has some nuance worth walking through so you can get a test result you can trust.

Why the medicine and the test collide

GLP-1 receptor agonists such as semaglutide, liraglutide, dulaglutide, and exenatide, along with the dual GIP/GLP-1 agonist tirzepatide, slow gastric emptying on purpose. That delayed clearance is part of how they curb appetite and steady the rise in blood sugar after a meal. It is a designed mechanism, not a glitch.

Here is the collision. A gastric emptying study measures the exact thing these drugs are built to slow. So while the medication is active in your system, the test can read as delayed or abnormal, and that abnormal number may reflect the drug rather than any underlying disease. Published review work in the Journal of Clinical Endocrinology and Metabolism makes this point directly: the slowing effect of these medications can confound diagnostic testing for delayed emptying. If the point of the scan is to figure out whether you have gastroparesis, a GLP-1 in the picture can muddy the very number the diagnosis hangs on.

What the scan actually measures, and why symptoms alone will not do

Scintigraphy is the objective, gold-standard way to measure gastric emptying. You eat a meal tagged with a small amount of tracer, and imaging tracks how quickly it leaves the stomach. The reason clinicians rely on it is simple: symptoms by themselves cannot confirm or rule out delayed emptying. Nausea and fullness can come from many sources, and plenty of people with real slowing feel fine.

That last part matters more than it sounds. Because the diagnosis leans on the measured number rather than on how you feel, anything that skews the number skews the diagnosis. A drug that predictably slows emptying is not a small footnote here. It sits right on top of the one measurement the whole study depends on.

"I feel fine now" does not mean "no measurable delay"

A fair question: what if you have been on a once-weekly GLP-1 for months and the early nausea is long gone? Does the effect fade? Somewhat. The slowing tends to be larger with short-acting agents and to attenuate over time with the long-acting, once-weekly ones, a pattern sometimes described as tachyphylaxis. So the effect is not frozen in place.

But attenuated is not absent. Reviews note that a measurable delay can still show up on scintigraphy after many months of therapy, even in someone who no longer reports nausea. Feeling symptom-free is not the same as having a clean, drug-free measurement. That gap is exactly why the testing team asks about the medication instead of just asking how your stomach feels lately.

Two different "hold the GLP-1" rules that get confused

People often blur together two separate sets of guidance. Keeping them apart will save you a lot of confusion.

The first is the gastric emptying scintigraphy protocol itself. The consensus recommendations from the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine direct that motility-altering medications be stopped for 48 hours before the test, and through imaging on the test day when it is safe to do so. The classes they name are opioids, anticholinergics, and prokinetics such as metoclopramide. That 48-hour rule is about test accuracy, and it predates GLP-1 drugs entirely.

The second set is procedure and anesthesia guidance. The American Society of Anesthesiologists has suggested holding daily GLP-1 agents on the day of a procedure and weekly agents for a week, and 2024 multi-society guidance moved toward individualized risk stratification, such as a 24-hour clear-liquid diet, rather than a blanket stop. The American Gastroenterological Association does not endorse a universal rule that everyone stop GLP-1s before endoscopy. Those recommendations exist to lower the risk of aspiration during sedation. They are not about getting an accurate emptying number. We cover that procedure side in our notes on GLP-1 medications before surgery and on GLP-1 medications and colonoscopy, because the reasoning there is different from the reasoning here.

The honest gap: there is no GLP-1-specific hold interval for this test

Now the part that gets glossed over. The existing gastric emptying scintigraphy guidelines do not name GLP-1 drugs at all. The nuclear medicine literature has openly flagged this. A 2024 article in the Journal of Nuclear Medicine Technology points out that GLP-1 agonists slow motility yet are not addressed in the current guidelines. So there is no single, society-endorsed number of days to hold a GLP-1 before an emptying study. Practice is set by the institution's protocol and the judgment of the ordering or interpreting clinician.

Half-life reasoning is where the discomfort shows. The standard 48-hour motility-med hold was never built for long-half-life drugs. Semaglutide's elimination half-life is roughly seven days, reported near 7.6 days. Pausing for a single week only drops the level to about half, still far above where it stops affecting the stomach. As a general pharmacology rule of thumb, full washout takes around five half-lives, which for semaglutide points to weeks, not days. Tirzepatide (Mounjaro and Zepbound, from Eli Lilly) has a half-life near five days and transiently delays emptying in a similar way, so it carries the same consideration. Treat that five-half-lives figure as general pharmacology, not a test guideline, and treat any specific hold length as institution and clinician dependent. Whether any hold fully restores your baseline motility is genuinely unproven, and reputable reviews say so plainly.

An abnormal result on the drug is usually the drug

Here is the reassuring frame. If your emptying study comes back delayed while you are actively on a GLP-1, that most often reflects the expected effect of the medication, not a diagnosis of chronic gastroparesis. The pharmacologic slowing these drugs produce is expected, it commonly eases over time, and it is not the same thing as pathologic gastroparesis. So a single abnormal scan taken on the medication is not a verdict. It is a number that needs the right context, which is precisely why the timing of any hold matters to the people reading your scan. If gastroparesis as a condition is what is really on your mind, we keep that separate in our piece on GLP-1 medications and gastroparesis.

What you can actually do, and who decides

You do not have to solve the pharmacology. You just have to coordinate well. A few practical steps:

• Tell the testing facility, clearly and early, that you are on a GLP-1. Give the drug name and how long you have been taking it.
• Ask for the written prep instructions and follow them exactly. If they specify a hold, that comes from their protocol.
• Loop in your prescriber before you change anything. Whether to pause the medication, for how long, and when to restart is a decision for the ordering or interpreting clinician together with the person who prescribes it, not something to do on your own.
• If you have diabetes, raise glucose control as its own item. Acute high blood sugar itself slows gastric emptying and can produce an abnormal study independent of any drug, so reasonable glucose control before the test is a real coordination point, and any change to diabetes medication belongs to your prescriber.

The one line to remember: this is the ordering clinician's call, made with your prescriber, and never a solo decision. That same principle applies to related GI questions, like whether reflux is the medication or something else, which we walk through in GLP-1 medications and acid reflux.

Where our clinic fits

At New Hope Weight Loss and Wellness, Dr. Anjmun Sharma, MD helps patients coordinate exactly this kind of situation. If another clinician has ordered a gastric emptying study or a broader motility workup, we work with that team on any hold and restart of your GLP-1, so you get a test you can trust and stay safe on your treatment plan. A GLP-1 is a tool for weight and metabolic health, not a treatment for an unrelated GI condition, and no medication should be started, stopped, or changed on your own.

Note on names and products: Ozempic and Wegovy (semaglutide) are trademarks of Novo Nordisk; Mounjaro and Zepbound (tirzepatide) are trademarks of Eli Lilly. We are not affiliated with either company. Compounded semaglutide and tirzepatide are not FDA-approved and not brand-identical, and results vary by individual.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.